There are 2934 resources available
4839 - Bevacizumab plus chemotherapy versus chemotherapy alone as first-line treatment for patients with RAS mutant unresectable colorectal liver-limited metastases- A single center randomized control trial
Presenter: Jianmin Xu
Session: Proffered Paper 1 – Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
Proffered Paper 1 – Gastrointestinal tumours, colorectal - Invited Discussant 523O and LBA31
Presenter: Claus-Henning Koehne
Session: Proffered Paper 1 – Gastrointestinal tumours, colorectal
Resources:
Slides
Webcast
Taking toxicity into account in the curative setting
Presenter: Nathan Cherny
Session: ESMO-MCBS: What have we learnt and how can we expand?
Resources:
Slides
Webcast
Challenges in grading based on disease free survival
Presenter: André Ilbawi
Session: ESMO-MCBS: What have we learnt and how can we expand?
Resources:
Slides
Webcast
Triple negative breast cancer (TNBC)
Presenter: Giuseppe Curigliano
Session: Novel therapeutic strategies in ABC: Immunotherapy, Antibody Drug Conjugates (ADCs) and beyond
Resources:
Slides
Webcast
DNA repair strategies: Beyond PARP inhibition
Presenter: Andrew Tutt
Session: Novel therapeutic strategies in ABC: Immunotherapy, Antibody Drug Conjugates (ADCs) and beyond
Resources:
Slides
Webcast
Optimal combination for firstline NSCLC
Presenter: Martin Reck
Session: Optimal delivery of immuno-oncology (I-O) in advanced NSCLC
Resources:
Slides
Webcast
Can we combine radiotherapy with I-O?
Presenter: Rafal Dziadziuszko
Session: Optimal delivery of immuno-oncology (I-O) in advanced NSCLC
Resources:
Slides
Webcast
2488 - Mutation tracking in circulating tumor DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies those at high risk of recurrence regardless of stage, lack of CDX2 expression and CMS subtype.
Presenter: Noelia Tarazona Llavero
Session: Proffered Paper 1 – Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
5561 - FOxTROT: an international randomised controlled trial in 1053 patients evaluating neoadjuvant chemotherapy (NAC) for colon cancer.
Presenter: Dion Morton
Session: Proffered Paper 1 – Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast